About
Steve Hall is a Board Member at Kymera Therapeutics. He brings more than 25 years of pharmaceutical experience from both multinational pharmaceutical companies and biotech organizations to Lilly Ventures. Prior to joining Lilly Ventures, Steve was Senior Vice President, Research and Development, at Serenex, Inc. where he was also a co-founder. There he recruited and led a team in developing a novel discovery technology and applied it to a project that advanced from a novel screen to first patient dosed in just over three years. This novel orally-active Hsp90 inhibitor was the subject of strong interest across the industry and led to the acquisition of Serenex by Pfizer in April 2008. Prior to joining Serenex, Steve was Site Director, Sphinx Labs, Eli Lilly where he oversaw lead generation efforts in the areas of combinatorial chemistry, automation, high-throughput screening, biomolecular research, and information technology. There he was a key member of a small team that developed an
Position in the VCSift Database
- • 3 investors at Lilly Ventures are tracked.
- • 421 investors hold the Venture Partner role in VCSift. Steve Hall is one of them.
- • 258 investors are based in Indianapolis, Indiana, United States.
Data sourced from 410,343 investor profiles. Updated July 2026.
Investment Focus
- Location
- Indianapolis, US
Contact Information
Find more investors like Steve
Search Investors